(Q40051568)

16 September 2017

title

Effects of anastrozole on cognitive performance in postmenopausal women: a randomised, double-blind chemoprevention trial (IBIS II). (English)

1 reference

16 September 2017

1 reference

5

1 reference

16 September 2017

6

1 reference

16 September 2017

7

1 reference

16 September 2017

4

Jack Cuzick

1 reference

16 September 2017

Valerie A Jenkins

1

1 reference

16 September 2017

Laurence M Ambroisine

series ordinal

2

1 reference

16 September 2017

Louise Atkins

series ordinal

3

1 reference

16 September 2017

publication date

1 September 2008

1 reference

Lancet Oncology Commission

16 September 2017

published in

1 reference

16 September 2017

volume

9

1 reference

16 September 2017

issue

10

1 reference

16 September 2017

page(s)

953-961

1 reference

Re: Tamoxifen for the Prevention of Breast Cancer: Current Status of the National Surgical Adjuvant Breast and Bowel Project P-1 Study

16 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970207-9

7 January 2021

Chemoprevention of breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970207-9

7 January 2021

Long-term results of tamoxifen prophylaxis for breast cancer--96-month follow-up of the randomized IBIS-I trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970207-9

7 January 2021

Estimates of the number of US women who could benefit from tamoxifen for breast cancer chemoprevention

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970207-9

7 January 2021

Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970207-9

7 January 2021

Does hormone therapy for the treatment of breast cancer have a detrimental effect on memory and cognition? A pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970207-9

7 January 2021

Memory impairments with adjuvant anastrozole versus tamoxifen in women with early-stage breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970207-9

7 January 2021

Neurocognitive performance in breast cancer survivors exposed to adjuvant chemotherapy and tamoxifen

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970207-9

7 January 2021

The (mis)classification of chemo-fog – methodological inconsistencies in the investigation of cognitive impairment after chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970207-9

7 January 2021

A 3-year prospective study of the effects of adjuvant treatments on cognition in women with early stage breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970207-9

7 January 2021

The Cognitive Failures Questionnaire (CFQ) and its correlates.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970207-9

7 January 2021

Assessment of quality of life in women undergoing hormonal therapy for breast cancer: validation of an endocrine symptom subscale for the FACT-B

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970207-9

7 January 2021

The association between neuropsychological impairment, self-perceived cognitive deficits, fatigue and health related quality of life in breast cancer survivors following standard adjuvant versus high-dose chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970207-9

7 January 2021

Empirical methods for assessing meaningful neuropsychological change following epilepsy surgery

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970207-9

7 January 2021

Change in cognitive function after chemotherapy: a prospective longitudinal study in breast cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970207-9

7 January 2021

Cognitive function during neoadjuvant chemotherapy for breast cancer: results of a prospective, multicenter, longitudinal study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970207-9

7 January 2021

Self-reported cognitive problems in women receiving adjuvant therapy for breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970207-9

7 January 2021

Experience of trauma, distress, and posttraumatic stress disorder among breast cancer patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970207-9

7 January 2021

Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970207-9

7 January 2021

Effect of raloxifene on prevention of dementia and cognitive impairment in older women: the Multiple Outcomes of Raloxifene Evaluation (MORE) randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970207-9

7 January 2021

The Women's Health Initiative Study of Cognitive Aging (WHISCA): a randomized clinical trial of the effects of hormone therapy on age-associated cognitive decline

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970207-9

7 January 2021

Effects of combination estrogen plus progestin hormone treatment on cognition and affect

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970207-9

7 January 2021

Oestrogen: brain ageing, cognition and neuropsychiatric disorder.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970207-9

7 January 2021

Tamoxifen for the prevention of breast cancer: psychosocial impact on women participating in two randomized controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970207-9

7 January 2021

Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: results of a questionnaire-based study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970207-9

7 January 2021

Cancer and cancer-therapy related cognitive dysfunction: an international perspective from the Venice cognitive workshop.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970207-9

7 January 2021

10.1016/S1470-2045(08)70207-9

Identifiers

DOI

1 reference

16 September 2017

1 reference